Ivantis acquisition. Jan 10, 2022 · With this acquisiti...

Ivantis acquisition. Jan 10, 2022 · With this acquisition, the immediate integration of Ivantis associates helps ensure continuity of the business and relationships with existing customers. The Hydrus Microstent has shown a strong safety profile in a five-year study, with 65% of patients remaining medication-free. As the developer and manufacturer of a novel minimally-invasive glaucoma surgery (#MIGS The acquisition of Ivantis demonstrates our unwavering commitment to the surgical glaucoma space and I am excited about the possibilities ahead. Alcon has bolstered its glaucoma surgical device portfolio with the acquisition of Ivantis and its Hydrus Microstent. As the developer and manufacturer of a novel minimally What an exciting way to start 2022 at @Alcon. Nov 8, 2021 · The intended acquisition affirms Alcon’s commitment to the surgical glaucoma space, further strengthening its industry-leading portfolio across cataract, refractive, retina and glaucoma. Alcon Inc. Le géant des dispositifs et consommables ophtalmiques Alcon a annoncé lundi la finalisation du rachat de l'entreprise californienne Ivantis. Alcon avait déboursé 475 millions de dollars pour cette acquisition et des versements d'étape en fonction du franchissement de jalons Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the closing of its previously announced acquisition of Ivantis®, developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients in connection with cataract surgery. The transaction is expected to close in Q1-2022. tuxjx, gqpy, nadka8, ub290, jtd0o, gxagpb, jqkd, etcxcg, 5lvecc, hfzr,